Clinical Trial Details
| Trial ID: | L6663 |
| Source ID: | NCT00184561 |
| Associated Drug: | Biphasic Insulin Aspart |
| Title: | Effectiveness and Safety of Biphasic Insulin Aspart 70/30 in Subjects With Type 2 Diabetes |
| Acronym: | |
| Status: | COMPLETED |
| Study Results: | NO |
| Results: | |
| Conditions: | Diabetes|Diabetes Mellitus, Type 2 |
| Interventions: | DRUG: biphasic insulin aspart |
| Outcome Measures: | Primary: Change in HbA1c, After 24 weeks of treatment | Secondary: Adverse events|Weight change|Fasting blood glucose|Hypoglycaemic episodes|2-hour postprandial blood glucose|after 24 weeks of treatment. |
| Sponsor/Collaborators: | Sponsor: Novo Nordisk A/S |
| Gender: | ALL |
| Age: | ADULT, OLDER_ADULT |
| Phases: | PHASE4 |
| Enrollment: | 321 |
| Study Type: | INTERVENTIONAL |
| Study Designs: | Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT |
| Start Date: | 2005-07 |
| Completion Date: | 2006-07 |
| Results First Posted: | |
| Last Update Posted: | 2017-01-06 |
| Locations: | Novo Nordisk Investigational Site, Beijing, Beijing, 100029, China|Novo Nordisk Investigational Site, Beijing, Beijing, 100730, China|Novo Nordisk Investigational Site, Guangzhou, Guangdong, 510120, China|Novo Nordisk Investigational Site, Wuhan, Hubei, 430022, China|Novo Nordisk Investigational Site, Nanjing, Jiangsu, 210008, China|Novo Nordisk Investigational Site, Xi'an, Shaanxi, 710032, China|Novo Nordisk Investigational Site, Shanghai, Shanghai, 200003, China|Novo Nordisk Investigational Site, Tianjin, Tianjin, 300070, China |
| URL: | https://clinicaltrials.gov/show/NCT00184561 |
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|